New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 31, 2014
11:18 EDTENDP, ACTEndo Health wins appeal ruling over Actavis related to Opana ER
A federal appeals court ruled that a district court erred in concluding that Roxane and Actavis (ACT) had an implied license to practice asserted patents related to Opana ER, which is sold in branded form by Endo Health (ENDP). The appeals court vacated the lower court ruling and remanded the suit for further judgment. Reference Link
News For ENDP;ACT From The Last 14 Days
Check below for free stories on ENDP;ACT the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 29, 2014
10:05 EDTENDPEndo shares remain overvalued, says Cantor
Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.
July 23, 2014
10:02 EDTENDP, ACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACT, ENDPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use